Genexine Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
3,713
46,432
20,577
60,806
11,957
Total Accounts Receivable
4,772
4,471
21,502
6,626
15,150
Inventories
149
108
192
129
-
Other Current Assets
294
689
1,146
4,303
1,785
Total Current Assets
8,928
51,700
43,417
71,864
28,892
Net Property, Plant & Equipment
19,864
23,816
24,345
23,604
41,295
Total Investments and Advances
11,748
17,947
38,183
54,494
63,477
Long-Term Note Receivable
-
-
480
-
-
Intangible Assets
11,199
20,650
35,676
4,696
4,193
Other Assets
4,108
-
-
3,935
2,876
Total Assets
55,847
114,112
142,101
158,593
140,734
ST Debt & Current Portion LT Debt
13,352
3,000
3,000
20,009
3,833
Accounts Payable
4
20
13
3,802
6,286
Other Current Liabilities
2,338
4,278
11,714
2,244
2,832
Total Current Liabilities
15,695
7,298
14,727
26,055
12,951
Long-Term Debt
-
4,257
-
-
11,458
Provision for Risks & Charges
344
913
757
845
816
Other Liabilities
1,505
711
851
1,568
1,600
Total Liabilities
17,544
13,179
16,334
28,468
26,825
Common Equity (Total)
38,303
100,932
125,392
130,125
113,909
Total Shareholders' Equity
38,303
100,932
125,766
130,125
113,909
Total Equity
38,303
100,932
125,766
130,125
113,909
Liabilities & Shareholders' Equity
55,847
114,112
142,101
158,593
140,734
Preferred Stock (Carrying Value)
-
-
375
-
-

About Genexine

View Profile
Address
4/F, Korea Bio Park Bldg. B
Seongnam-si GY 13488
Korea, Republic Of
Employees -
Website http://www.genexine.com
Updated 09/14/2018
Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam, South Korea.